We have located links that may give you full text access.
Percutaneous osteoplasty combined with radioiodine therapy as a treatment for bone metastasis developing after differentiated thyroid carcinoma.
Clinical Nuclear Medicine 2012 June
BACKGROUND: Bone metastasis developing after differentiated thyroid carcinoma (DTC) is common, and in most cases, this condition leads to osteolysis. However, treatment of bone metastases in DTC patients is a great challenge. The purpose of this study was to evaluate the effectiveness of percutaneous osteoplasty (POP) combined with radioiodine therapy for treating bone metastasis developing after DTC.
PATIENTS AND METHODS: We retrospectively studied 8 patients who had undergone POP combined with radioiodine therapy for bone metastases after DTC. All patients underwent total thyroidectomy and were administered an oral dose of 131I (3.7 GBq, 100 mCi) for ablation of the residual thyroid. Thereafter, a POP was performed at 2 to 3 months followed by 2 to 5 sessions of radioiodine therapy every 4 to 6 months after the first 131I therapy. The therapeutic effectiveness of this treatment was evaluated on the basis of the changes in serum thyroglobulin (Tg) level and imaging characteristics, palliation of bone pain, and alleviation of neurologic symptoms.
RESULTS: After POP, the mean serum Tg level decreased by 86.0% (range, 68.1%-99.3%). The mean serum Tg level markedly declined further by 67.4% (range, 37.1%-90.2%) after repeated radioiodine therapy. All the patients experienced immediate and substantial alleviation of bone pain and neurologic symptoms, and their quality of life markedly improved. The bone-destructive lesions were filled with bone cement to enhance skeletal stability. No severe complications developed.
CONCLUSION: POP, a minimally invasive procedure, combined with radioiodine therapy seems to be highly effective in providing pain relief and bone stability and in improving the quality of life of DTC patients with bone metastases. After POP, radioiodine therapy is essential.
PATIENTS AND METHODS: We retrospectively studied 8 patients who had undergone POP combined with radioiodine therapy for bone metastases after DTC. All patients underwent total thyroidectomy and were administered an oral dose of 131I (3.7 GBq, 100 mCi) for ablation of the residual thyroid. Thereafter, a POP was performed at 2 to 3 months followed by 2 to 5 sessions of radioiodine therapy every 4 to 6 months after the first 131I therapy. The therapeutic effectiveness of this treatment was evaluated on the basis of the changes in serum thyroglobulin (Tg) level and imaging characteristics, palliation of bone pain, and alleviation of neurologic symptoms.
RESULTS: After POP, the mean serum Tg level decreased by 86.0% (range, 68.1%-99.3%). The mean serum Tg level markedly declined further by 67.4% (range, 37.1%-90.2%) after repeated radioiodine therapy. All the patients experienced immediate and substantial alleviation of bone pain and neurologic symptoms, and their quality of life markedly improved. The bone-destructive lesions were filled with bone cement to enhance skeletal stability. No severe complications developed.
CONCLUSION: POP, a minimally invasive procedure, combined with radioiodine therapy seems to be highly effective in providing pain relief and bone stability and in improving the quality of life of DTC patients with bone metastases. After POP, radioiodine therapy is essential.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.British Journal of Haematology 2024 April 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app